MetaVia Framtida tillväxt

Future kriterier kontrolleras 0/6

MetaVia s intäkter förväntas minska vid 20.4% EPS förväntas tillväxt med 22.8% per år.

Viktig information

-20.4%

Tillväxttakt i vinsten

22.79%

Tillväxttakt för EPS

Biotechs vinsttillväxt	25.2%
Intäkternas tillväxttakt	n/a
Framtida avkastning på eget kapital	n/a
Bevakning av analytiker	Low
Senast uppdaterad	31 Mar 2026

Senaste uppdateringarna om framtida tillväxt

Recent updates

Analysartikel • Sep 17

We're Keeping An Eye On MetaVia's (NASDAQ:MTVA) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analysartikel • Oct 03

Here's Why We're A Bit Worried About NeuroBo Pharmaceuticals' (NASDAQ:NRBO) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Seeking Alpha • Sep 29

NeuroBo Pharmaceuticals regains compliance with Nasdaq minimum bid price requirement

NeuroBo Pharmaceuticals (NASDAQ:NRBO) received Nasdaq notification indicating that the company has evidenced full compliance with the minimum bid price requirement As a result, the listing matter has been closed. Shares are trading up 4% premarket.

Analysartikel • Sep 14

Here's Why NeuroBo Pharmaceuticals (NASDAQ:NRBO) Must Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Seeking Alpha • Sep 12

NeuroBo Pharmaceuticals climbs higher on announcing reverse stock split

NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares are surging 56% on announcing a 1-for-30 reverse split of its common stock, par value $0.001. The trading on a split adjusted basis will commence on Nasdaq from September 13, 2022. The number of authorized shares of the company's common stock will remain at 100M, while the number of outstanding shares will be reduced from ~26.7M to ~0.9M.

Seeking Alpha • Nov 25

NeuroBo Pharmaceuticals: Advancing Therapies For Viral, Neuropathic And Neurodegenerative Diseases

NeuroBo Pharmaceuticals is advancing novel disease-modifying therapies for viral, neuropathic and neurodegenerative diseases. The Company has four candidates in the development pipeline, with the lead candidate ANA001 being advanced for treatment of moderate COVID-19. The Company seeks an EUA for the lead candidate, failing which it intends to pursue an NDA via a 505(b)(2) pathway.

Analysartikel • Dec 21

Here's What NeuroBo Pharmaceuticals, Inc.'s (NASDAQ:NRBO) Shareholder Ownership Structure Looks Like

If you want to know who really controls NeuroBo Pharmaceuticals, Inc. ( NASDAQ:NRBO ), then you'll have to look at the...

Prognoser för vinst- och omsättningstillväxt

NasdaqCM:MTVA - Analytikernas framtida uppskattningar och tidigare finansiella data (USD Millions )
Datum	Intäkter	Intäkter	Fritt kassaflöde	Kassaflöde från rörelsen	Genomsnittligt Antal analytiker
12/31/2025	N/A	-13	-16	-16	N/A
9/30/2025	N/A	-16	-16	-16	N/A
6/30/2025	N/A	-18	-19	-19	N/A
3/31/2025	N/A	-25	-23	-23	N/A
12/31/2024	N/A	-28	-25	-25	N/A
9/30/2024	N/A	-28	-23	-23	N/A
6/30/2024	N/A	-26	-20	-20	N/A
3/31/2024	N/A	-17	-15	-15	N/A
12/31/2023	N/A	-12	-11	-11	N/A
9/30/2023	N/A	-12	-9	-9	N/A
6/30/2023	N/A	-11	-9	-9	N/A
3/31/2023	N/A	-14	-9	-9	N/A
12/31/2022	N/A	-14	-12	-12	N/A
9/30/2022	N/A	-14	-13	-13	N/A
6/30/2022	N/A	-14	-13	-13	N/A
3/31/2022	N/A	-15	-14	-14	N/A
12/31/2021	N/A	-15	-15	-15	N/A
9/30/2021	N/A	-30	-15	-15	N/A
6/30/2021	N/A	-30	-14	-14	N/A
3/31/2021	N/A	-28	-13	-13	N/A
12/31/2020	N/A	-30	-11	-11	N/A
9/30/2020	N/A	-23	-10	-10	N/A
6/30/2020	N/A	-24	-11	-11	N/A
3/31/2020	N/A	-24	-10	-10	N/A
12/31/2019	N/A	-21	N/A	-7	N/A
9/30/2019	N/A	-12	N/A	-10	N/A
6/30/2019	N/A	-11	N/A	-9	N/A
3/31/2019	N/A	-13	N/A	-12	N/A
12/31/2018	N/A	-16	N/A	-14	N/A

Analytiker Framtid Tillväxt Prognoser

Intäkter kontra sparande: MTVA förväntas förbli olönsam under de kommande 3 åren.

Resultat vs marknad: MTVA förväntas förbli olönsam under de kommande 3 åren.

Höga tillväxtresultat: MTVA förväntas förbli olönsam under de kommande 3 åren.

Intäkt vs marknad: Otillräcklig data för att avgöra om MTVA s intäkter förväntas växa snabbare än marknaden för US.

Hög tillväxtintäkter: MTVA förväntas inte ha några intäkter nästa år.

Tillväxtprognoser för vinst per aktie

Framtida avkastning på eget kapital

Framtida ROE: Otillräcklig data för att avgöra om MTVA s avkastning på eget kapital förväntas bli hög om tre år

Upptäck tillväxtföretag

Företagsanalys och finansiella data Status

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2026/05/15 03:18
Aktiekurs vid dagens slut	2026/05/15 00:00
Intäkter	2026/03/31
Årlig intjäning	2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

^* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

MetaVia Inc. bevakas av 3 analytiker. 3 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

Analytiker	Institution
Andrew Fein	H.C. Wainwright & Co.
Jason McCarthy	Maxim Group
David Bautz	Zacks Small-Cap Research

MetaVia Framtida tillväxt

Future kriterier kontrolleras 0/6

Viktig information

Senaste uppdateringarna om framtida tillväxt

Price target decreased by 16% to US$132

Price target increased by 40% to US$20.00

Price target decreased by 7.5% to US$14.33

Price target decreased by 35% to US$17.33

No longer forecast to breakeven

No longer forecast to breakeven

Recent updates

MetaVia Inc., Annual General Meeting, Jun 08, 2026

Metavia Inc Doses First Patient in Higher-Dose Phase 1 Study of Da-1726

Metavia Inc. Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726

MetaVia Inc Expands Global Patent Protection For Vanoglipel Supporting Metabolic And Liver Disease Therapy Through 2035

MetaVia Inc. Announces Positive AI-Modeling Results from its Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets for Vanoglipel

MetaVia Inc. has completed a Composite Units Offering in the amount of $8.099988 million.

Metavia Inc. Reports Positive Statistically Significant Results from Its Phase 1B Clinical Trial of DA-1726 in Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile

Price target decreased by 16% to US$132

Nasdaq Grants Extension to MetaVia Inc. to Regain Minimum Bid Price Compliance

MetaVia Inc. Presents Positive New Phase 2A Data on Vanoglipel (Da-1241) in Patients with Presumed Mash At the Aasld the Liver Meeting®? 2025

We're Keeping An Eye On MetaVia's (NASDAQ:MTVA) Cash Burn Rate

Price target increased by 40% to US$20.00

New major risk - Financial position

MetaVia Inc. Extends 48 Mg Mad Portion of Its Phase 1 Clinical Trial of Da-1726 for the Treatment of Obesity to 8 Weeks and Announces Fifth Weekly Dose in First Patient

MetaVia Inc. Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum Tolerated Dose

MetaVia Inc. Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination with Efruxifermin at the ADA's 85th Scientific Session

MetaVia Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

MetaVia Inc., Annual General Meeting, Jun 30, 2025

Price target decreased by 7.5% to US$14.33

MetaVia Inc. announced that it has received $9.995395 million in funding

MetaVia Inc. announced that it expects to receive $9.995395 million in funding

Metavia Inc. Presents Data on DA-1241, GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed Mash, at the EASL Congress 2025

MetaVia Inc. Reports Additional Positive Top-Line Results from the MAD Part 2 of Its Phase 1 Study of DA-1726

New major risk - Market cap size

MetaVia Inc. Announces Clinical Trials

Price target decreased by 35% to US$17.33

MetaVia Inc. Announces Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH

New major risk - Financial position

NeuroBo Pharmaceuticals, Inc. Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Here's Why We're A Bit Worried About NeuroBo Pharmaceuticals' (NASDAQ:NRBO) Cash Burn Situation

Neurobo Pharmaceuticals Announces Positive Top-Line Data from the Sad Part 1 of Its Phase 1 Clinical Trial Evaluating Da-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals, Inc. Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals, Inc. announced that it has received $17.000005 million in funding from Dong-A ST Co., Ltd.

NeuroBo Pharmaceuticals, Inc. Doses First Patient in the MAD Part 2 of its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $3.000001 million.

NeuroBo Pharmaceuticals, Inc., Annual General Meeting, Jun 07, 2024

NeuroBo Pharmaceuticals, Inc. Doses First Patient in Its Phase 1 Clinical Trial Evaluating Da-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals, Inc. Completes Enrollment of Part 1 of Its Phase 2A Clinical Trial Evaluating DA-1241 for the Treatment of Mash

NeuroBo Pharmaceuticals, Inc. Receives Safety Review Committee Approval to Continue with Its Phase 2A Clinical Trial Evaluating DA-1241 for the Treatment of Mash

NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment

Neurobo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of Da-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2A Clinical Trial Evaluating Da-1241 for the Treatment of Mash

NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals, Inc. Appoints James P. Tursi to its Board of Directors and as Member of Nominating and Corporate Governance Committee

NeuroBo Pharmaceuticals, Inc. Appoints Marshall H. Woodworth as Acting Chief Financial Officer

NeuroBo Pharmaceuticals, Inc. Announces Resignation of Na Yeon (Irene) Kim from the Board of Directors

NeuroBo Pharmaceuticals, Inc. Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of Nash

NeuroBo Pharmaceuticals, Inc. Announces Executive Changes

NeuroBo Pharmaceuticals Receives 180-Day Extension to February 5, 2024 from Nasdaq to Regain Compliance with the Minimum Bid Price Requirement

Neurobo Pharmaceuticals, Inc. Receives First Site IRB Approval for Its Phase 2A Clinical Trial Evaluating DA-1241 for the Treatment of NASH

NeuroBo Pharmaceuticals, Inc., Annual General Meeting, Jun 28, 2023

Neurobo Pharmaceuticals, Inc. Appoints Pharmaceutical Industry Executive, Mark A. Glickman, to Its Board of Directors

NeuroBo Pharmaceuticals Receives Non-Compliance Notice from Nasdaq

NeuroBo Pharmaceuticals, Inc. Appoints Joseph Hooker as President

NeuroBo Pharmaceuticals, Inc. announced that it has received $15 million in funding from Dong-A ST Co., Ltd.

NeuroBo Pharmaceuticals Compliant with All Applicable Nasdaq Listing Criteria

NeuroBo Pharmaceuticals regains compliance with Nasdaq minimum bid price requirement

NeuroBo Pharmaceuticals, Inc. announced that it expects to receive $37 million in funding from Dong-A ST Co., Ltd.

Here's Why NeuroBo Pharmaceuticals (NASDAQ:NRBO) Must Use Its Cash Wisely

NeuroBo Pharmaceuticals climbs higher on announcing reverse stock split

NeuroBo Pharmaceuticals, Inc., Annual General Meeting, Jun 09, 2022

Neurobo Pharmaceuticals, Inc. Appoints Matthew Bardin as Senior Vice President Operations

High number of new and inexperienced directors

NeuroBo Pharmaceuticals, Inc. Appoints D. Gordon Strickland to its Board of Directors

NeuroBo Pharmaceuticals: Advancing Therapies For Viral, Neuropathic And Neurodegenerative Diseases

No longer forecast to breakeven

Independent Director Jeong Gyun Oh has left the company

No longer forecast to breakeven

Price target decreased to US$16.00

NeuroBo Pharmaceuticals, Inc.(NasdaqCM:NRBO) dropped from Russell 3000E Index